examined the effect of the CCR5 antagonist, maraviroc, on lymphocyte function and chemotaxis in vitro as well as performed a phase 1/2 study on 38 high-risk patients who received standard immune suppression along with maraviroc as GVHD prophylaxis (76). The gene discussed is CCR5; the disease is graft versus host disease.